Research programme: protein phosphatase 5 inhibitors - SupremeCure Pharma

Drug Profile

Research programme: protein phosphatase 5 inhibitors - SupremeCure Pharma

Alternative Names: PX - SupremeCure Pharma

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SupremeCure Pharma
  • Class Antineoplastics
  • Mechanism of Action Protein-phosphatase-5-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cholangiocarcinoma; Hepatocellular carcinoma; Non-small cell lung cancer

Most Recent Events

  • 11 Apr 2018 Early research in Cholangiocarcinoma in Taiwan (unspecified route) (SupremeCure Pharma pipeline, April 2018)
  • 11 Apr 2018 Early research in Hepatocellular carcinoma in Taiwan (unspecified route) (SupremeCure Pharma pipeline, April 2018)
  • 11 Apr 2018 Early research in Non-small cell lung cancer in Taiwan (unspecified route) (SupremeCure Pharma pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top